pilsicainide

structure given in first source

Also Known As:

1H-pyrrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, hydrochloride (1:1); 1H-pyrrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, hydrochloride hemihydrate; N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride; SUN 1165; SUN-1165; pilsicainide hydrochloride; pilsicainide hydrochloride hemihydrate; pilsicainide hydrochloride hydrate; tetrahydro-1H-pyrrolizine-7a(5H)-aceto-2',6'-xylidide

Networked: 127 relevant articles (11 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - Anilides: 22
      - Acetanilides: 7
        Lidocaine: 9718
        pilsicainide: 127
- Amides: 2428
  - Anilides: 22
    - Acetanilides: 7
      - Lidocaine: 9718
        pilsicainide: 127

Experts

1.	Morita, Hiroshi: 5 articles (10/2018 - 11/2003)
2.	Aizawa, Yoshifusa: 4 articles (09/2014 - 02/2002)
3.	Kumagai, Koichiro: 4 articles (06/2006 - 12/2004)
4.	Nishii, Nobuhiro: 3 articles (10/2018 - 11/2003)
5.	Watanabe, Atsuyuki: 3 articles (10/2018 - 11/2003)
6.	Ikeda, Takanori: 3 articles (08/2017 - 02/2003)
7.	Komatsu, Takashi: 3 articles (08/2017 - 06/2006)
8.	Yamashita, Takeshi: 3 articles (08/2017 - 01/2002)
9.	Shimizu, Akihiko: 3 articles (01/2016 - 01/2008)
10.	Ueyama, Takeshi: 3 articles (01/2016 - 01/2008)

Related Diseases

1.	Atrial Fibrillation 08/01/2003 - "Pilsicainide hydrochloride is effective in patients with atrial fibrillation of short duration with small left atrium and rapid ventricular response." 10/01/2001 - "These results suggest that pilsicainide has a high degree of efficacy for maintaining normal sinus rhythm in patients with the day type onset of paroxysmal atrial fibrillation." 11/01/2000 - "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF). " 10/01/2001 - "[Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset]." 06/01/2006 - "Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II."
2.	Ventricular Tachycardia 11/01/2004 - "His serum pilsicainide concentration was significantly decreased by these treatments, and the prolongation of the QTc and ventricular tachycardia improved in parallel to the decrease in the serum pilsicainide level. " 10/01/2018 - "Successful treatment for various arrhythmias in an older patient treated with pilsicainide for paroxysmal supraventricular tachycardia." 01/01/2012 - "Pilsicainide-induced polymorphic ventricular tachycardia." 03/05/2010 - "Pilsicainide is a class Ic antiarrhythmic agent used for the treatment of supraventricular and ventricular tachycardia. " 05/01/2008 - "Administration of pilsicainide (1 mg/kg) exaggerated J-ST-segment elevation, caused simultaneous long and short QT intervals in the RVOT, and induced polymorphic ventricular tachycardia (VT) and T wave alternans (TWA). "
3.	Heart Diseases (Heart Disease) 07/01/2010 - "The symptoms, syncope, and type 1 electrocardiogram after pilsicainide test were independently associated with the electrophysiological substrate of VF in patients without apparent heart disease." 08/01/2017 - "This study compared the efficacy of flecainide versus pilsicainide in reducing the frequency of AF and improving quality of life (QOL) in symptomatic paroxysmal AF patients without structural heart disease. " 01/01/2002 - "Despite the absence of structural heart diseases, his ECG revealed J wave and ST segment elevation in the inferior leads, which showed circadian variation and were augmented by the sodium channel blocker, pilsicainide. " 12/01/1997 - "In 12 patients without organic heart disease, monophasic action potentials (MAPs) were recorded at the right ventricular endocardium using a contact electrode before and after the administration of disopyramide (n = 6, 2 mg/kg, i.v.) or pilsicainide (class Ic agents, n = 4, 1 mg/kg, i.v., and n = 2, 150 mg, po) while the stimulus frequency was abruptly increased from 100/min to 150/min. The rise time, defined as the interval from the pacing pulse to the first peak deflection of the monophasic action potential, and the ORS width were measured simultaneously. " 01/01/2021 - "Thirteen trials included patients with some degree of heart failure; 19 included patients with some degree of ischaemic heart disease vs. placebo or rate-control (32% success) at 8 h, flecainide [73%, network odds ratio (OR) 7.6, 95% credible interval (CrI) 4.4-14.0], propafenone (70%, OR 4.6, CrI 2.9-7.3), and pilsicainide (59%, OR 10.0, CrI 1.8-69.0), but not amiodarone (28%, OR 1.0, CrI 0.4-2.8) were superior. "
4.	Atrial Flutter (Flutter, Atrial) 06/01/2006 - "One patient in the pilsicainide group developed an atrial flutter without any hemodynamic deterioration. " 02/18/2003 - "In some experiments, pilsicainide converts AF to persistent atrial flutter." 02/18/2003 - "On the maps, all "unorganized" AFs were terminated with the excitation of the core of the mother rotor by an outside wavefront, whereas in preparations with atrial flutter, pilsicainide did not terminate its activity. " 07/01/2005 - "Long-term efficacy of hybrid pharmacologic and ablation therapy in patients with pilsicainide-induced atrial flutter." 04/17/2009 - "Atrial fibrillation was terminated at 5.9 +/- 2.2 min in 16 patients (Group A) with a decrease in the average of mean dominant frequencies at all sites from 5.80 +/- 0.72 to 3.57 +/- 0.63 Hz, was converted to atrial flutter at 7.3 +/- 1.4 min in 5 (Group B) with a decrease in the average dominant frequency from 5.83 +/- 0.48 to 3.08 +/- 0.19 Hz, and was not terminated in the other 13 (Group C) despite the average dominant frequency decrease from 6.59 +/- 0.76 to 4.42 +/- 0.52 Hz. In 14 of the 21 Groups A and B patients (67%), mean dominant frequencies at all recording sites were < 4.0 after pilsicainide, while they were < 4.0 in 1 of the 13 Group C patients (8%, P < 0.01). "
5.	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/01/2020 - "Pilsicainide administration induced coved-type ST elevation and VF triggered by a single premature ventricular contraction. " 09/01/2014 - "Pilsicainide induced the typical ECG pattern and premature ventricular beats (PVBs) of the same morphology as VT. " 03/05/2010 - "Both oral and intravenous pilsicainide have demonstrated efficacy in ventricular tachyarrhythmias, including ventricular extrasystole. " 03/01/1992 - "The intraventricular conduction time (CT) was determined by excitation induced by a ventricular stimulation at various coupling intervals from 200 to 1,000 ms. SUN-1165 (1 and 3 mg/kg) showed a marked reduction in the frequency of ventricular ectopic beats 24 h after LAD ligation and was more potent than lidocaine. " 04/01/1988 - "SUN 1165, lorcainide, and disopyramide slowed ventricular conduction time of extrasystoles at all coupling intervals of 800-250 ms. On the other hand, mexiletine slowed conduction time at short coupling intervals of 500-250 ms. These findings suggest that, like lorcainide, SUN 1165 belongs to class Ic antiarrhythmic agents, and that SUN 1165 and lorcainide as well as disopyramide with slow and intermediate kinetics and mexiletine with fast kinetics may inhibit ventricular extrasystoles conducted at long and short range of coupling intervals, respectively."

Related Drugs and Biologics

1.	Flecainide (Tambocor)
2.	cifenline (cibenzoline)
3.	Anti-Arrhythmia Agents
4.	Magnesium Sulfate (Sulfate, Magnesium)
5.	Sodium Channel Blockers
6.	pilsicainide
7.	Propafenone (Rythmol)
8.	C-Reactive Protein
9.	Amiodarone (Amiodarona)
10.	Albumins

Related Therapies and Procedures

1.	Therapeutics
2.	Electric Countershock (Cardioversion)
3.	Intravenous Injections
4.	Intravenous Infusions
5.	Oral Administration